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Abstract: Penicillin allergies are among of the most commonly reported allergies, yet only 10% of
these patients are truly allergic. This leads to potential inadvertent negative consequences for patients
and makes treatment decisions challenging for clinicians. Thus, allergy assessment and penicillin
skin testing (PST) are important management strategies to reconcile and clarify labeled penicillin
allergies. While PST is more common in the inpatient setting where the results will immediately
impact antibiotic management, this process is becoming of increasing importance in the outpatient
setting. PST in the outpatient setting allows clinicians to proactively de-label and educate patients
accordingly so beta-lactam antibiotics may be appropriately prescribed when necessary for future
infections. While allergists have primarily been responsible for PST in the outpatient setting, there is
an increasing role for pharmacist involvement in the process. This review highlights the importance
of penicillin allergy assessments, considerations for PST in the outpatient setting, education and
advocacy for patients and clinicians, and the pharmacist’s role in outpatient PST.
Keywords: penicillin; allergy; skin testing; outpatient; pharmacist; antimicrobial stewardship
1. Introduction
Penicillin allergy is the most commonly reported antibiotic allergy, with approximately 10% of
the general population being labeled as penicillin allergic [1]. However, nearly 90% of patients with
reported penicillin allergies are not type I IgE-mediated reactions [1,2]. Documentation of inaccurate
penicillin allergies is associated with unintended negative consequences, especially for common
infections in the outpatient setting where treatment with beta-lactam antibiotics is preferred in both
pediatric and adult patients [3]. These include increased use of alternative or broader spectrum
antibiotics with the potential for additional adverse effects including Clostridioides difficile-associated
diarrhea (CDAD), increased medical costs, worse clinical outcomes, or increased development of
bacterial resistance [4–7]. While the majority of penicillin allergy outcome data is from the inpatient
setting, patients with a penicillin allergy in the outpatient setting are also more likely to receive
additional antibiotics, have higher antibiotic costs, and utilize more healthcare resources [8,9].
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One of the primary issues is that penicillin allergies are often misdiagnosed or mislabeled as true
allergies, and when present, diminish over time in most patients [10]. Clinicians and patients are
frequently unaware that penicillin allergies are misdiagnosed and that patients may be able to still
tolerate penicillin or other beta-lactam antibiotics. This is an opportunity for pharmacist involvement
in the outpatient setting to perform comprehensive penicillin allergy assessments, increase referrals
for penicillin skin testing (PST), perform PST, educate clinicians and patients, and ensure appropriate
allergy documentation [11,12]. PST is a reasonable, safe procedure that is already being performed in
outpatient allergy clinics, but has a potential to reach even more patients with pharmacist involvement.
This public health initiative would allow patients to be de-labeled and proactively made aware of their
penicillin allergy history so that beta-lactam antibiotics can be appropriately prescribed when needed
for a future infection in either an outpatient or inpatient setting. Therefore, the focus of this article is to
review and highlight penicillin allergy assessment and PST opportunities in the outpatient setting.
This review includes references identified via PubMed using the search terms “skin tests”, “penicillin”,
and “outpatient”, but is not a comprehensive review of all available literature. The focus is on areas
where pharmacists can improve the care of a patient labeled with a penicillin allergy. A detailed review
of penicillin allergy assessment and PST in the inpatient setting, including the PST process, is described
elsewhere [13].
2. Penicillin Allergy Interview Assessment
Appropriate assessment of reported penicillin allergies should begin with a thorough interview,
including the following components: characterization of the reaction, likelihood of causality, IgE-
vs. non-IgE-mediated reaction, timeframe of the reaction, receipt of other antibiotics, and history of
skin testing and other drug allergy testing [1,10,14]. These questions are essential to risk stratify the
likelihood of a true penicillin allergy and options for reconciliation. This interview is an excellent
opportunity to provide education to patients on the potential negative consequences of reported
penicillin allergies and the statistics on the number of patients who report penicillin allergies compared
to those that are truly allergic [1–3]. Many patients may be labeled with a penicillin allergy, but they
may have received a similar antibiotic in the past such as amoxicillin or another oral penicillin-type
antibiotic. It is important to recognize the specific antibiotic that the patient received since there are
different cross-reactivity potentials across the beta-lactam antibiotics based on similarities in their R-1
side chain of their chemical structure [15,16]. A discussion on R-1 side chains and cross-reactivity
among beta-lactam antibiotics is outside the scope of this article; however, Chaudhry and colleagues
provide a thorough review on this topic elsewhere [17]. A detailed description of the reaction is
also necessary since some reactions may be intolerances rather than true allergies. Additionally, this
helps to determine the likelihood of causality to penicillin and stratify if patients experienced a type
I IgE-mediated reaction or if it was a less severe reaction. Patients may get confused with allergic
reaction terminology and may not be able to differentiate between a less severe reaction such as a
maculopapular rash versus a potentially severe reaction such as hives. Patients may also have difficulty
in recalling the specific details of the reaction, particularly if the reaction was several years ago or was
deemed low severity. Thus, pharmacists should consider asking patients to describe the reaction in
an open-ended fashion, then follow-up with closed-ended questions which elucidate the differences
between these reactions [14]. This should result in the most accurate description of the reaction.
Patients who had a previous reaction may not have a subsequent reaction due to waning immunity
over time, especially among patients where the reaction occurred decades ago [1]. Approximately
80% of patients lose sensitivity of their initial, true allergic reaction after 10 years [10]. Thus, it is
important for pharmacists and patients to identify the timeframe of the penicillin reaction. Many
patients are also frequently unaware they may have received and tolerated antibiotics similar to
penicillin. However, patients may not able to recall the specific beta-lactam antibiotic they received.
Therefore, pharmacists should consider listing some common oral beta-lactam antibiotics using both
the generic and brand name, where appropriate, in an effort to increase the likelihood of recollection.
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Pharmacists and patients may also review pharmacy records to assess antibiotic prescription history.
Despite these efforts, patients may still not be able to accurately answer all of these questions, which
makes appropriate assessment for clinicians challenging, especially when many of the answers to the
questions are unknown. In patients deemed higher risk for a true allergic reaction or with an unknown
allergy history, PST is a helpful management option in the outpatient setting [18–21].
3. Clinicians Involved in PST
PST in the outpatient setting has historically been performed in allergist-run specialty clinics [22,23].
Pharmacists currently have a limited role, especially in outpatient PST [18]. A survey of Boards of
Pharmacy in 2017 revealed that only 18 states allowed pharmacists to perform PST based on their
state’s scope of practice, with an additional 8 states potentially allowing permission based on certain
requirements and regulations [18]. For example, New York State’s current legislation allows for the
administration of intramuscular injections, but does not allow pharmacists to administer intradermal
injections. As such, PST is a great opportunity for professional pharmacy organizations at the state
and national level to advocate for pharmacists to perform PST, especially with The Joint Commission’s
requirement for expansion of antimicrobial stewardship in ambulatory care settings in 2020 [24].
In states where pharmacists are not allowed to perform PST, ambulatory care and infectious diseases
pharmacists can still play an essential role in collaborative patient referral opportunities for outpatient
PST, consideration of direct oral challenges for select patients, and the provision of patient and provider
education surrounding penicillin allergy.
4. Referrals for PST
A proactive, elective referral to an allergist or clinic performing PST in the outpatient setting
helps avoid potential complications associated with a penicillin allergy history during hospitalization.
In 2017, a position statement from the Penicillin Allergy in Antibiotic Resistance Workgroup of the
American Academy of Allergy, Asthma, & Immunology recommended routine PST in patients with a
self-reported penicillin allergy [25]. Despite this recommendation, routine PST is not common practice.
A study of an urban, adult outpatient clinic referred only 6% (78/1348) of penicillin allergic patients
to an allergy specialist [26]. Barriers to elective referrals included lack of knowledge regarding PST
availability and limited clinics that were accessible to perform PST in various areas.
There are no clinical studies currently available that focus on successful penicillin allergy referral
programs by pharmacists. The majority of studies focus on preoperative allergy assessment in the
cardiac and orthopedic populations [27,28]. A systematic review and meta-analysis identified four
studies that observed a significantly lower rate of non-beta-lactam antibiotic usage when preoperative
antibiotic allergy testing protocols were employed compared to standard of care (odds ratio of 3.64
[95% confidence interval, 2.67–4.98]; p < 0.0001) [29]. A recent study by Wyles and colleagues reviewed
preoperative antibiotics for total knee and hip arthroplasties and the impact of antibiotic allergy
testing on cefazolin use and subsequent infection rates [30]. A total of 97% (2493/2576) of PST tested
patients were cleared to receive cefazolin as their antibiotic prophylaxis regimen. The increased use of
cefazolin resulted in a 32% lower rate of prosthetic joint infections. Based on these data, the authors
recommended perioperative testing and clearance in all orthopedic patients with either a penicillin or
a cephalosporin allergy.
In the non-surgical population, routine penicillin allergy referral to a PST provider is limited.
The Miami Veterans Affairs Health Care System proactively referred outpatients with a self-reported
penicillin allergy to their allergy clinic for PST testing. Of 41 veterans who underwent testing, 93%
were PST negative, which resulted in a 39% reduction in broad-spectrum antibiotic use over a 3-year
follow-up period [31]. Other potential target populations for PST referrals include patients in long-term
care facilities (LTCF), urgent care clinics, pediatric clinics, and emergency departments. Many patients
residing in LTCF with labeled penicillin allergies are likely to be prescribed alternative antibiotics
to beta-lactams for infections, such as fluoroquinolones. This alternative exposure is of particular
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concern given this patient population may be even more susceptible to potential adverse effects
from fluroquinolones [32]. As such, this is an area for consultant pharmacists and LTCF clinicians
to proactively assess penicillin allergies and perform PST, where appropriate, to potentially prevent
CDAD and other adverse effects secondary to alternative antibiotic use.
Urgent care clinics are often recognized as a convenient resource for many patients to seek
healthcare services for acute care issues including infections. However, many patients with penicillin
allergies who seek urgent care clinics for infectious-related problems may not have the same referral
opportunity and provider relationship since many of these patients may not have an established
primary care provider [33]. Pediatric patients also seek acute care visits for common infections, such as
acute otitis media, where beta-lactams are considered standard of care; however, penicillin allergies
can preclude the optimal therapeutic recommendations in this patient population [34]. As such, PST
in these outpatient settings is important to consider despite limited available data. In addition to
provider referrals, there may also be a role for healthcare plan referral to capitalize on lower utilization
of healthcare resources associated with a negative PST. Macy and colleagues identified an annual
savings per patient of $1915.40 in healthcare expenditures in a patient population with higher baseline
healthcare utilization [35].
5. Time, Cost, and Reimbursement Considerations for PST
5.1. Clinician Time
The time dedicated by pharmacists to perform PST is dependent on the testing performed,
personnel involved in the preparation of the products, and involvement of ancillary staff [18].
To calculate the pharmacist time involved with PST, there needs to be an estimate of the time required to
perform an accurate and comprehensive allergy history interview, prepare the PST contents, perform a
prick test with a 15-min wait time for results, and perform intradermal testing with a 15-min wait time
for results. If all test results are negative, clinicians may choose to perform a direct, oral challenge with
amoxicillin. This requires an additional 60 min or more for patient monitoring. After the completion of
the PST, patient education time, documentation time, and dedicated time to inform other providers of
results should also be included. This time would also be prolonged if the patient developed an adverse
reaction to the PST procedure. However, the likelihood of a systemic reaction occurring from PST is
rare and has been reported as 0.16% among nearly 20,000 patients exposed to both major and minor
determinants [36].
The time required to perform a detailed allergy history is highly variable, with one allergy group
calculating an average of 13.8 min [37]. Drug mixing time typically requires less than 5 min, but could
be longer if batching is performed. A recent survey of North American providers estimated a median
time of 20 min to perform the prick and intradermal test respectively [38]. A direct, oral challenge
can be performed with a one- or two-step method. A one-step method involves administration of
a therapeutic dose of amoxicillin and monitoring patients for 60 min or more. A two-step method
involves giving the patient a fraction (10%) of a therapeutic dose with a 30-min observation period
followed by administration of the full therapeutic dose (90%) with 60-min post-observation time.
Overall, the total time required is variable based on the patient history, testing procedure performed,
and clinic workflow, but can range anywhere from 45–120 min [37].
5.2. Supply Cost
The cost of PST supplies is approximately $140 to $160 per patient (Table 1). The following
rescue medications are not included in this per patient cost estimate: epinephrine auto-injector device,
diphenhydramine oral, prednisone/methylprednisolone oral, and albuterol inhaler. Labor and supply
cost vary based on the clinicians responsible for performing the procedure and supplies. A time-driven,
activity-based, cost model with a board-certified allergist or immunologist performing outpatient PST
with a one-step amoxicillin oral challenge resulted in a base case cost of $220 [37]. Personnel, supply,
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and space costs were $97.96, $119.08, and $2.82, respectively. However, the estimated cost decreased to
$168 if a registered nurse prepared the supplies and a nurse practitioner performed the procedure.
This cost is balanced with the direct cost savings after PST by using beta-lactam antibiotics instead of
alternative antibiotics that may be more expensive or unnecessarily broad-spectrum [35]. Furthermore,
indirect cost benefits include a lower risk of hospital-acquired infections, decreased hospital length of
stay, and less emergency department and outpatient provider visits [35,39].
Table 1. Cost of specific penicillin skin testing contents.
Drug Contents of Penicillin Skin Testing Average Wholesale Price ($)
Benzylpenicilloyl polylysine (0.25 mL) ampule (PRE-PEN) $138.00
Penicillin G Potassium 10,000 IU/mL (5 million units) $15.19
Amoxicillin 500 mg (250 mg/5 mL) $0.06 per mL
Amoxicillin 500 mg capsule $0.19–5.88
Histamine base (1 mg/mL) 5 mL $204.40 ($2.00 per test)
5.3. PST Coding, Billing, and Reimbursement
Outpatient PST is a reimbursable process whereas inpatient testing is part of hospitalization
costs and dependent on diagnostic related grouping reimbursement. PST uses current procedural
terminology (CPT) code 95018 for each prick/intradermal test, and CPT 95076 for the oral ingestion
challenge that requires up to 61–120 min of observation. Code 95018 is reimbursed $18.95 on average
by Centers for Medicare and Medicaid Services and would total $170.55 for four skin pricks and 5
intradermal tests (personal communication with ALK-Abello, Inc., Round Rock, TX, USA). Evaluation
and Management codes L1 to L5 are also used, as appropriate, based on new patients, follow-up, and
number of visits utilized. There are International Classification of Diseases, Tenth Revision codes
T36.OX5A, T36.OX5D, Z88.0, and Z87.892 for adverse effect of penicillins initial encounter, subsequent
encounter, allergy status, and personal history of anaphylaxis, respectively.
6. Penicillin Allergy Documentation
Allergy documentation in the electronic medical record (EMR) is an important component of PST.
The ideal approach to allergy documentation varies depending on the health system involved. Once
PST has been performed, most institutions resolve and inactivate the penicillin allergy from the EMR. It
is important to input the date and results of PST into the patient’s problem list and insert a placeholder
in the allergy section of the EMR with the same information in an effort to prevent relabeling of the
penicillin allergy. Some institutions also have the capability to add in an electronic alert that will appear
if a provider is entering a penicillin allergy in the allergy section of a patient’s chart who previously
had a negative PST [40,41]. In order to further assist in the prevention of penicillin allergy relabeling,
PST programs need to take a multi-faceted approach that involves communication to patient and their
families, providers within and outside the healthcare network, and community pharmacies. However,
this can be challenging since this process can involve several healthcare professionals and family
members at various locations.
There are also several potential opportunities for allergy documentation errors to occur since
multiple members of the healthcare team have access to modify these records [42]. Blumenthal and
colleagues observed that allergy deletions occurred infrequently by healthcare team members and
50% of allergy alerts occurred for medications that patients tolerated previously [42]. Furthermore,
the penicillin allergy may reappear with subsequent healthcare encounters if allergy record updates
following PST are not documented correctly and comprehensively. After a negative PST, 49% (26/53) of
patients did not have their penicillin allergy removed from the medical record [43]. An observational
study in a healthcare system composed of hospital, LTCF, and primary care providers found that 36%
(20/55) of patients with a negative PST had their allergies re-documented with a median follow-up
period of one year. Interestingly, all 21 of the LTCF patients still had a penicillin allergy documented
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in the EMR [44]. Documentation errors also occur in the pediatric population. Vyles and colleagues
performed a follow-up study of 100 parents and primary care providers of children with a negative
PST performed in a pediatric emergency department [45]. Of 98 respondents, 52% of children still had
a penicillin allergy documented in the primary care physician’s office, despite 80% (65/81) of parents
reporting that they notified the primary care physician of the negative test. Thus, accurate allergy
documentation following PST and communication of these results to other healthcare professionals is
essential to prevent inaccurate penicillin allergy re-labeling and improve future antibiotic use.
Bourke and colleagues studied a subgroup of patients before and after the implementation and
dissemination of detailed instructions to both the patient and primary care provider [46]. The printed
instructions contained each antibiotic tested and clear recommendations on the specific antibiotics that
should be used and avoided based on the patient’s PST results. This document improved adherence to
allergy label modifications in the PST negative groups following recommendation with 68% (74/109)
before and 85% (46/54) after with a median follow-up period of 15 months (p = 0.02). The results of
PST should also be communicated to patients’ community pharmacies. If this step is omitted and
a patient presents to the pharmacy with a prescription for a beta-lactam antibiotic with a penicillin
allergy listed in the patient profile, a potentially unnecessary phone call will be made by the pharmacist
to the provider to clarify the beta-lactam prescription or recommend an alternative antibiotic. Some
PST programs also perform a post-test telephone call by a pharmacist to other healthcare professionals
to reinforce the results of PST [41].
7. Education
7.1. Patient Education
While appropriate allergy documentation and communication of PST results across the continuum
of care are important, patient education that clearly explains the results and ramifications of the PST
procedure is also necessary to improve the accuracy and longevity of allergy documentation. If this
is not done effectively, patients with a negative PST will continue to label themselves as penicillin
allergic and refuse beta-lactam antibiotics. A follow-up study of 784 allergy clinic patients who had
PST and a 5-day oral amoxicillin challenge were reviewed for subsequent penicillin use after PST.
Of the 163 patients who did not receive a penicillin during the follow-up period, 45 (27%) refused
to use a penicillin because they believed that it would not be safe or did not fully understand the
PST results [47]. A similar study was performed at a tertiary academic outpatient practice over a
3-year period [48]. A total of 41% (12/29) of patients who were PST negative continued to avoid
beta-lactam antibiotics. The survey reported this was related to either their personal (42%) or primary
care physician’s beliefs (58%). Interestingly, six of the 12 patients would also inform a new provider
that they had a penicillin allergy. PST negative patients were also asked if they were aware of the
antibiotics they could be prescribed. Of the 29 patients, 18 stated all beta-lactam antibiotics, 5 stated
penicillin only, and 6 did not know. This represents an excellent opportunity for pharmacists and other
clinicians to provide education on beta-lactam antibiotics that patients are likely to tolerate following a
negative PST. As such, it is necessary to ensure that patients are aware of and can interpret the results
of a negative PST to help them serve as their own healthcare advocates [49].
Wallet cards following PST may also assist in patient education as well as disseminating PST
results to other healthcare professionals [40]. These cards may also contain the generic and brand names
of beta-lactam antibiotics that PST revealed the patient should tolerate. This additional information will
provide clarity to other providers and pharmacies in an effort to avoid interpretation errors. A city-wide
antimicrobial management program in Savannah, GA, provides information to healthcare providers on
beta-lactam antibiotics (penicillins, cephalosporins, and carbapenems) that were previously tolerated
by patients [40]. However, there is still room for improvement in identifying more effective educational
strategies to explain the risks associated with reported penicillin allergies.
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7.2. Clinician Education
Primary care providers offices are considered the central repository for allergy information in
the EMR. The results of inpatient/outpatient PST results are commonly forwarded to primary care
providers. This information is then forwarded to community pharmacies, specialists, and hospitals.
Studies have indicated that despite the results of negative PST, primary care physicians do not feel
comfortable prescribing beta-lactam antibiotics [50]. This may be due to a lack of knowledge on
the sensitivity and specificity of PST results and the lack of drug allergy education in their training
programs [51]. To assess providers knowledge of penicillin allergies and interpretation of PST results,
Prematta and colleagues conducted a survey to review physician responses to a variety of allergy case
scenarios [52]. The authors concluded that many physicians are unaware of the utility of a PST and
this is an area where further education would be valuable. As part of the Antibiotic Prescribing and
Use in Doctor’s Offices, the Centers of Disease Control and Prevention developed physician education
on the evaluation and diagnosis of a penicillin allergy that highlights the negative predictive value
that approaches 100% following PST with the major and minor determinant with a subsequent direct,
oral challenge [10]. Furthermore, the University of South Carolina College of Pharmacy offers a 15-h
penicillin allergy assessment and skin testing certificate program to train and certify clinicians [53].
This represents an excellent opportunity for clinicians to take advantage of to improve their knowledge
of the issues surrounding penicillin allergies and to perform appropriate penicillin allergy assessments
and PST.
8. Penicillin Allergy Patient Advocacy and the Role of the Pharmacist the Outpatient Setting
The outpatient setting serves as an excellent opportunity to promote patient advocacy and
education of penicillin allergies. As previously described, healthcare professionals such as primary
care providers, pharmacists, and nurses in the outpatient setting should support and provide penicillin
allergy educational strategies for patients. Education may include, but is not limited to penicillin allergy
statistics, potential unintended consequences of labeled penicillin allergies, and referral locations
where a structured penicillin allergy assessment and PST may be performed. Providers and nurses
within patients’ primary care providers’ offices and patients’ community pharmacists serve as an
excellent mechanism to promote penicillin allergy awareness and education in the outpatient setting.
Public information dissemination via different media platforms such as news and radio stations are
also another strategy to reach patients in the outpatient setting in an effort to increase awareness of the
concerns associated with penicillin allergies. Patients could be encouraged to be their own healthcare
advocates and pursue a formal penicillin allergy assessment. This proactive approach is important
for PST negative or penicillin de-labeled patients to be involved and informed of their allergy history
while helping disseminate their results to healthcare professionals.
To date, pharmacist involvement in PST services has been predominately performed in the inpatient
setting where the results will directly impact clinical decision making for antibiotic therapy [18]. PST is
generally considered a safe service, especially when scratch testing is performed before intradermal
testing and serves an excellent opportunity to potentially de-label penicillin allergies through a
non-acute approach in the outpatient setting. Board-certified allergists have primarily been responsible
for screening, performing, and interpreting PST for patients in the outpatient setting. However,
allergists are a specialty service that are often unavailable in several healthcare systems. As such,
this provides a great opportunity for pharmacists to be involved with PST in the outpatient setting.
To date, the role of pharmacists in outpatient PST has been limited due to challenges including on
scope of practice, billing, education, training, and personnel resources. However, pharmacists are
well-positioned to be involved in PST services given their drug expertise, involvement within the
healthcare team, and patient interaction opportunities. Pharmacists also practice in a wide array of
outpatient practice settings including, but not limited to, community pharmacies, ambulatory care,
and urgent care clinics that commonly serve diverse patient populations.
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The community pharmacy setting is often recognized by patients as their first healthcare
professional resource since patients can readily seek advice and counseling from a licensed pharmacist.
Pharmacists in this role serve as an excellent resource to educate patients on penicillin allergies,
perform structured allergy assessment interviews, and evaluate the potential opportunity for PST.
Pharmacists are already counseling patients on medications, and this may be an excellent opportunity
to screen patients with a labeled penicillin allergy for an appropriate allergy assessment interview.
Based on the penicillin allergy assessment interview, community pharmacists can clarify incomplete
or inaccurate allergy data since they have access to add, edit, and remove allergy information in a
patients’ prescription record as well as the EMR in certain health systems. Pharmacists, especially
those practicing in the community settings, should also take an active role in increasing referral rates to
available PST outpatient clinics. One strategy to accomplish this may be to identify penicillin allergic
patients from electronic prescribing records and provide them with a community resource outlining
a list of available clinics that perform PST. As such, community pharmacies may be encouraged to
develop a professional relationship with local allergists for potential referrals for PST.
The role of pharmacists in the community setting are also continuing to expand by administration
of several immunizations and various clinical services including point-of-care testing and screening.
PST may serve as a future opportunity for community pharmacists to perform, yet certain barriers
currently exist that hinder this practice. As discussed previously, pharmacists’ scope of practice varies
among different State Board of Pharmacies, and PST services are primarily restricted to the inpatient
setting. Professional pharmacy organizations are well-positioned to advocate for pharmacists to
perform PST, especially as outpatient antimicrobial stewardship continues to grow. Time and space
logistics can also be challenging for community pharmacists. However, many community pharmacies
already have a private immunization or consultation room available that may offer sufficient space to
perform PST. While PST can be time consuming with taking 60 min or more, the majority of this time
requirement is spent observing the patient for a reaction. During this time period, pharmacists can still
perform their other responsibilities with periodic check-ins for observation of a reaction. Pharmacy
technicians and ancillary staff can also help prepare or batch the contents necessary to perform PST so
that they are readily available for the pharmacist to perform the service when needed.
While a pharmacy may view PST as a financial disincentive from the loss of the pharmacists’ time
and supplies required, these costs may be further offset by decreased healthcare utilization costs and
offer a potential billing opportunity for a clinical service performed by pharmacists [18,54]. Pharmacists
providing service in the ambulatory care and urgent care clinic setting may also be well-positioned
to perform PST with similar considerations. Although barriers to implementation of pharmacists
performing PST currently exist, pharmacists and professional pharmacy organization can continue to
advocate for PST due to the potential clinical and economic benefits for patients and pharmacies as
part of antimicrobial stewardship endeavors in the outpatient setting [40].
9. Conclusions
While PST and penicillin allergy assessment has largely been performed in acute care settings
where results will immediately impact antibiotic therapy decisions, there is an increasing role
for implementation in the outpatient setting to improve antibiotic prescribing. Pharmacists are
well-positioned to be involved in PST and penicillin allergy assessments as part of antimicrobial
stewardship initiatives in the outpatient setting. However, more data and strategies to mitigate barriers
to these approaches are necessary to further advance these clinical and economic benefits for patients.
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